Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

60.37 +0.39 (+0.65%)

Delayed Quote Updated: 3:59 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

38 39 Next >

Drug Troubles ↗

January 28, 2022

The drug sector has both good news and bad.

Via Talk Markets

Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗

January 25, 2022

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (...

Via Benzinga

These OTC Securities Had the Most Trading Activity in December ↗

January 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be i...

Via Benzinga

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)

January 25, 2022

From Genentech

Via Business Wire

The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months

January 24, 2022

From Genentech

Via Business Wire

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...

Via Talk Markets

Chopped Stocks ↗

January 18, 2022

The day's theme is sell tech and buy banks.

Via Talk Markets

MLK Day Global News ↗

January 17, 2022

In Q4 China's GDP growth rate halved to 4%.

Via Talk Markets

More Serious Matters ↗

January 14, 2022

Wall Street fell on new worries about inflation and a drop in retail sales levels.

Via Talk Markets

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

January 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...

Via FinancialNewsMedia

Topics Death

Interest Rate Hikes And Stocks ↗

January 12, 2022

Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.

Via Talk Markets

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗

January 12, 2022

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...

Via Benzinga

Happy New Year - Sunday Edition ↗

January 02, 2022

Starting a new year - we look at tech, pharma and mining stocks and their goings-on.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio ↗

December 30, 2021

As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February.

Via Talk Markets

Boxing Day Finance ↗

December 27, 2021

Today we saw the Dow Jones move up over 36,000.

Via Talk Markets

Free COVID Tests: What Stocks Will Benefit? ↗

December 23, 2021

The government hasn’t announced yet what company or companies it will be buying from, but there are several businesses involved in producing these kits.

Via Talk Markets

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

Dreaming Of A Red Christmas ↗

December 20, 2021

The stock market is reacting with lots of selling to the weekend's news.

Via Talk Markets

Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗

December 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)...

Via Benzinga

Raising Rates ↗

December 16, 2021

The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries.

Via Talk Markets

These OTC Securities Had the Most Trading Activity in November ↗

December 16, 2021

Photo by Markus Winkler on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Novartis Launches New Share Buyback Program Of Up To $15B ↗

December 16, 2021

Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth...

Via Benzinga

After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗

December 15, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape...

Via Benzinga

Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗

December 14, 2021

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen...

Via Benzinga

Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma

December 14, 2021

From Genentech

Via Business Wire

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗

December 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...

Via Benzinga

Biotech Playbook 2021: No Help From Small Caps In Q4 ↗

December 14, 2021

Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...

Via Talk Markets

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings ↗

December 13, 2021

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%...

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.